

Supplemental Digital Content 5. Percentage of participants with anti-tetanus toxoid concentrations ≥ 0.1 IU/mL and geometric mean concentrations 1 month post-vaccination (ATP cohort for immunogenicity at Month 73)

Timepoint	N	HibMenC group		N	Hib+MCC group	
		≥ 0.1 IU/mL	GMC		≥ 0.1 IU/mL	GMC
		% (95% CI)	(95% CI)		% (95% CI)	(95% CI)
M73	103	100 (96.5–100)	15.6 (13.1–18.6)	34	100 (89.7–100)	12.5 (8.4–18.7)

ATP, according-to-protocol; IU, international unit; GMC, geometric mean concentration; CI, confidence interval.

Note: HibMenC group, received *Haemophilus influenzae* type b-meningococcal serogroup C-tetanus toxoid conjugate (HibMenC-TT) and measles, mumps and rubella (MMR) vaccines in the primary study and meningococcal serogroups A, C, W, Y-tetanus toxoid conjugate vaccine (MenACWY-TT) in the extension study; Hib+MCC group, received *Haemophilus influenzae* type b conjugated to tetanus toxoid (Hib-TT), meningococcal serogroup C conjugated to CRM₁₉₇ (MCC-CRM₁₉₇) and MMR vaccines in the primary study and MenACWY-TT in the extension study. Month 73, 1 month post-vaccination.